Export and Pharma Stocks Cheer as India–EFTA Trade Pact Comes Into Force

The long-awaited India–EFTA (European Free Trade Association) trade pact, involving Switzerland, Norway, Iceland, and Liechtenstein, has officially come into effect, unlocking a major opportunity for Indian exporters across multiple industries. This agreement provides significant tariff reductions and smoother regulatory access for Indian goods and services in Europe’s high-income markets. Pharmaceutical giants like

, , Cipla, and are expected to be among the biggest beneficiaries, as the deal will streamline drug approvals and reduce duties on generic medicines exported to EFTA countries. This could translate into higher export margins and stronger growth in Europe — a region that already accounts for a sizeable chunk of their revenue. In the auto and engineering space, Tata Motors, , and may gain from increased demand for Indian automotive components and machinery exports, supported by better market access and supply chain diversification in Europe. Similarly, , , and Navin Fluorine stand to benefit from chemical and specialty material exports that align with Europe’s push for cleaner, cost-efficient sourcing. The pact also bodes well for the gems and jewellery sector, with Titan Company, Kalyan Jewellers, and positioned to benefit from reduced tariffs and improved export logistics to Switzerland — one of the world’s major jewellery hubs.